Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The bone marrow plasma cell labeling index by flow cytometry.

B Pope1, R Brown, J Gibson

  • 1Institute of Haematology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.

Cytometry
|December 10, 1999
PubMed
Summary

Flow cytometry offers a faster, more objective method for assessing multiple myeloma prognosis. This technique improves upon traditional microscopy by providing more reliable plasma cell labeling index values.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Melphalan exposure and outcome in obese and non-obese adults with myeloma. A study of pharmacokinetics and pharmacodynamics.

Bone marrow transplantation·2020
Same author

Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR.

Leukemia·2016
Same author

Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study.

Leukemia·2016
Same author

Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade.

Leukemia·2016
Same author

Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group.

Leukemia·2015
Same author

The failure of immune checkpoint blockade in multiple myeloma with PD-1 inhibitors in a phase 1 study.

Leukemia·2015

Area of Science:

  • Hematology
  • Immunology
  • Oncology

Background:

  • The bone marrow plasma cell labeling index is crucial for multiple myeloma prognosis.
  • Traditional immunofluorescence microscopy is time-consuming and subjective.

Purpose of the Study:

  • To evaluate flow cytometry adaptations for assessing the plasma cell labeling index.
  • To compare different methods for S-phase detection and plasma cell identification.

Main Methods:

  • Compared bromodeoxyuridine and propidium iodide methods for S-phase detection.
  • Compared CD38-FITC, CD38-FITC + CD138-FITC, and CD38-biotin + streptavidin FITC for plasma cell identification.
  • Correlated flow cytometry results with traditional microscopy.

Main Results:

Related Experiment Videos

  • CD38-biotin + streptavidin FITC demonstrated superior fluorescent intensity for plasma cell identification.
  • Propidium iodide staining correlated well with microscopy (r=0.71, P<0.0001).
  • Bromodeoxyuridine method showed no correlation with microscopy (r=0.09, P=NS).
  • Flow cytometry methods yielded higher labeling index values than microscopy.
  • A new threshold of >4% labeling index is proposed, replacing the traditional >1%.

Conclusions:

  • Flow cytometry provides a more objective and efficient method for determining the plasma cell labeling index in multiple myeloma.
  • The propidium iodide DNA method combined with CD38-biotin + streptavidin FITC is a superior flow cytometry approach.
  • This enhanced method offers additional prognostic data, including ploidy and cell cycle status.